Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer

S.A. Kraaijenga; O. Hamming-Vrieze; S. Verheijen; E. Lamers; L. van der Molen; F.J. Hilgers; M.W. van den Brekel; W.D. Heemsbergen

doi:https://doi.org/10.1002/hed.25573

Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer

S.A. Kraaijenga, O. Hamming-Vrieze, S. Verheijen, E. Lamers, L. van der Molen, F.J. Hilgers, M.W. van den Brekel, W.D. Heemsbergen

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Scopus)

Abstract

Background: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM).

Methods: Pretreatment and post-treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity-modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut-off values and risk groups.

Results: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO).

Conclusions: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.

Original language	English
Pages (from-to)	1387-1394
Number of pages	8
Journal	Head and Neck
Volume	41
Issue number	5
Early online date	16 Jan 2019
DOIs	https://doi.org/10.1002/hed.25573
Publication status	Published - May 2019

Keywords

NTCP
dose effect
head and neck cancer
radiotherapy
trismus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1002/hed.25573

https://pure.uva.nl/ws/files/44859917/Kraaijenga_et_al_2019_Head_Neck.pdfLicence: Article 25fa Dutch Copyright Act

Cite this

@article{7102ed9f4339481fa8c5bd0971d70f83,

title = "Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer",

abstract = "Background: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM). Methods: Pretreatment and post-treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity-modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut-off values and risk groups. Results: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO). Conclusions: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.",

keywords = "NTCP, dose effect, head and neck cancer, radiotherapy, trismus",

author = "S.A. Kraaijenga and O. Hamming-Vrieze and S. Verheijen and E. Lamers and {van der Molen}, L. and F.J. Hilgers and {van den Brekel}, M.W. and W.D. Heemsbergen",

note = "With supplementary file",

year = "2019",

month = may,

doi = "https://doi.org/10.1002/hed.25573",

language = "English",

volume = "41",

pages = "1387--1394",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer

AU - Kraaijenga, S.A.

AU - Hamming-Vrieze, O.

AU - Verheijen, S.

AU - Lamers, E.

AU - van der Molen, L.

AU - Hilgers, F.J.

AU - van den Brekel, M.W.

AU - Heemsbergen, W.D.

N1 - With supplementary file

PY - 2019/5

Y1 - 2019/5

N2 - Background: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM). Methods: Pretreatment and post-treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity-modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut-off values and risk groups. Results: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO). Conclusions: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.

AB - Background: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM). Methods: Pretreatment and post-treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity-modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut-off values and risk groups. Results: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO). Conclusions: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.

KW - NTCP

KW - dose effect

KW - head and neck cancer

KW - radiotherapy

KW - trismus

UR - http://www.scopus.com/inward/record.url?scp=85060133531&partnerID=8YFLogxK

UR - https://pure.uva.nl/ws/files/140673727/hed25573_sup_0001_supinfo.docx

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060133531&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30652390

U2 - https://doi.org/10.1002/hed.25573

DO - https://doi.org/10.1002/hed.25573

M3 - Article

C2 - 30652390

SN - 1043-3074

VL - 41

SP - 1387

EP - 1394

JO - Head and Neck

JF - Head and Neck

IS - 5

ER -

Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this